What is Trially?
Trially operates as an AI-native platform designed to enhance the speed and accuracy of matching and enrolling patients into clinical trials. By optimizing enrollment processes, reducing screen failures, and streamlining prescreening efforts, Trially aims to accelerate clinical research. The platform is trusted by clinical sites, sponsors, and physicians, leveraging secure and compliant AI technology to revolutionize the way clinical trials are conducted.
How much funding has Trially raised?
Trially has raised a total of $4.7M across 1 funding round:
Seed
$4.7M
Seed (2025): $4.7M with participation from The Council, Alpaca, Looking Glass Capital, Flyover Capital, Blu Ventures, Gaingels, Redbud Brands, and Atria
Key Investors in Trially
The Council
The Council is a participant in the Venture Capital & Private Equity industry, contributing to Trially's funding round.
Alpaca
Alpaca VC, a venture capital firm specializing in real estate and commerce startups, has provided backing to Trially, indicating a potential interest in the intersection of technology and healthcare infrastructure.
Looking Glass Capital
Looking Glass Capital, an investment firm focused on mission-driven founders in early-stage development, has invested in Trially, aligning with their focus on ventures addressing significant challenges, potentially in the health sector.
What's next for Trially?
The substantial enterprise-level funding Trially has garnered suggests a pivotal growth phase, likely moving beyond early-stage development into a scaling or expansion phase. This capital will likely be directed towards further technological development of its AI capabilities, expanding its market reach to more clinical trial stakeholders, and potentially forging strategic partnerships to integrate its platform more deeply into the clinical research ecosystem. The focus on AI-native solutions positions Trially to capitalize on the increasing demand for efficiency and data-driven insights in healthcare research.
See full Trially company page
